According to the expression profile of HLA-E/β2m, the therapeutic response at 3 months was not statistically different between the 2 groups of tumors HLA-E+vs HLA-E−, regardless of the tumor site considered, primary or paired metastatic (Table 5). This evidence concerns the gene HLA-E and neoplasm.